908856-77-9

Upstream product

• 100-39-0 benzyl bromide 
• 55399-93-4 (2S,3R,4S)-4-hydroxyisoleucine 
• 790701-97-2 ethyl (2S,3R)-2-((4-methoxyphenyl)amino)-3-methyl-4-oxopentanoate 
• 885054-30-8 ethyl (2S,3R)-2-amino-3-methyl-4-oxopentanoate 

Downstream Products

• 55527-86-1 (3S,4R,5S)-3-amino-4,5-dimethyldihydrofuran-2(3H)-one 

Relevant academic research and scientific papers

Total synthesis and absolute structure of N55, a positive modulator of GLP-1 signaling

Glucagon-like peptide-1 (GLP-1) signaling is an established therapeutic target for type 2 diabetes mellitus (T2DM). We developed a 7-step synthesis of N55, a positive modulator of GLP-1 signaling isolated from fenugreek (Trigonella foenum-graecum) seeds,

Analogs of 4-hydroxyisoleucine and uses thereof

The invention relates to analogs of 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The analogs of the invention stimulate both glucose uptake and insulin secretion, and may thus be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism, including diabetes mellitus (type 1 and type 2 diabetes), pre-diabetes, and Metabolic Syndrome.

Compounds and compositions for use in the prevention and treatment of obesity and related syndromes

The invention relates to 4-hydroxyisoleucine, isomers, analogs, lactones, salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. More particularly, the invention relates to the use of those compounds in the prevention and treatment of obesity and related syndromes.